Logo image of INCY

INCYTE CORP (INCY) Stock Price, Quote, News and Overview

NASDAQ:INCY - Nasdaq - US45337C1027 - Common Stock - Currency: USD

65.3  +1.49 (+2.34%)

After market: 65.3 0 (0%)

INCY Quote, Performance and Key Statistics

INCYTE CORP

NASDAQ:INCY (5/20/2025, 8:05:45 PM)

After market: 65.3 0 (0%)

65.3

+1.49 (+2.34%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High83.95
52 Week Low53.56
Market Cap12.64B
Shares193.57M
Float188.82M
Yearly DividendN/A
Dividend YieldN/A
PE35.49
Fwd PE9.35
Earnings (Next)07-28 2025-07-28/bmo
IPO12-06 1993-12-06


INCY short term performance overview.The bars show the price performance of INCY in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 10

INCY long term performance overview.The bars show the price performance of INCY in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 5 -5 10 -10

The current stock price of INCY is 65.3 USD. In the past month the price increased by 13.8%. In the past year, price increased by 13.94%.

INCYTE CORP / INCY Daily stock chart

INCY Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18 327.00B
AMGN AMGEN INC 13.25 147.86B
GILD GILEAD SCIENCES INC 14.1 135.84B
VRTX VERTEX PHARMACEUTICALS INC N/A 114.96B
REGN REGENERON PHARMACEUTICALS 13.87 66.38B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 37.94B
ARGX ARGENX SE - ADR 98.52 35.31B
ONC BEIGENE LTD-ADR 5.89 25.53B
BNTX BIONTECH SE-ADR N/A 24.45B
NTRA NATERA INC N/A 21.01B
BIIB BIOGEN INC 8.25 19.13B
SMMT SUMMIT THERAPEUTICS INC N/A 18.11B

About INCY

Company Profile

INCY logo image Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,617 full-time employees. The firm operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The firm's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.

Company Info

INCYTE CORP

1801 Augustine Cut-Off

Wilmington DELAWARE 19803 US

CEO: Herve Hoppenot

Employees: 2617

INCY Company Website

INCY Investor Relations

Phone: 13024986700

INCYTE CORP / INCY FAQ

What is the stock price of INCYTE CORP today?

The current stock price of INCY is 65.3 USD. The price increased by 2.34% in the last trading session.


What is the ticker symbol for INCYTE CORP stock?

The exchange symbol of INCYTE CORP is INCY and it is listed on the Nasdaq exchange.


On which exchange is INCY stock listed?

INCY stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for INCYTE CORP stock?

33 analysts have analysed INCY and the average price target is 75.54 USD. This implies a price increase of 15.68% is expected in the next year compared to the current price of 65.3. Check the INCYTE CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is INCYTE CORP worth?

INCYTE CORP (INCY) has a market capitalization of 12.64B USD. This makes INCY a Large Cap stock.


How many employees does INCYTE CORP have?

INCYTE CORP (INCY) currently has 2617 employees.


What are the support and resistance levels for INCYTE CORP (INCY) stock?

INCYTE CORP (INCY) has a support level at 61.63 and a resistance level at 65.31. Check the full technical report for a detailed analysis of INCY support and resistance levels.


Is INCYTE CORP (INCY) expected to grow?

The Revenue of INCYTE CORP (INCY) is expected to grow by 12.03% in the next year. Check the estimates tab for more information on the INCY EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy INCYTE CORP (INCY) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does INCYTE CORP (INCY) stock pay dividends?

INCY does not pay a dividend.


When does INCYTE CORP (INCY) report earnings?

INCYTE CORP (INCY) will report earnings on 2025-07-28, before the market open.


What is the Price/Earnings (PE) ratio of INCYTE CORP (INCY)?

The PE ratio for INCYTE CORP (INCY) is 35.49. This is based on the reported non-GAAP earnings per share of 1.84 and the current share price of 65.3 USD. Check the full fundamental report for a full analysis of the valuation metrics for INCY.


What is the Short Interest ratio of INCYTE CORP (INCY) stock?

The outstanding short interest for INCYTE CORP (INCY) is 3.39% of its float. Check the ownership tab for more information on the INCY short interest.


INCY Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to INCY. When comparing the yearly performance of all stocks, INCY turns out to be only a medium performer in the overall market: it outperformed 58.22% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

INCY Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to INCY. INCY gets an excellent profitability rating and is at the same time showing great financial health properties.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

INCY Financial Highlights

Over the last trailing twelve months INCY reported a non-GAAP Earnings per Share(EPS) of 1.84. The EPS decreased by -51.45% compared to the year before.


Industry RankSector Rank
PM (TTM) 0.48%
ROA 0.37%
ROE 0.58%
Debt/Equity 0.01
Chartmill High Growth Momentum
EPS Q2Q%81.25%
Sales Q2Q%19.53%
EPS 1Y (TTM)-51.45%
Revenue 1Y (TTM)17.13%

INCY Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 74% to INCY. The Buy consensus is the average rating of analysts ratings from 33 analysts.

For the next year, analysts expect an EPS growth of 348.67% and a revenue growth 12.03% for INCY


Ownership
Inst Owners97.01%
Ins Owners1.98%
Short Float %3.39%
Short Ratio3
Analysts
Analysts73.94
Price Target75.54 (15.68%)
EPS Next Y348.67%
Revenue Next Year12.03%